56 studies found for:    Open Studies | "Peritoneal Diseases"
Show Display Options
Rank Status Study
1 Unknown  Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin;   Drug: ifosfamide;   Procedure: hyperthermia treatment
2 Recruiting Quality of Life Questionnaire for Pediatric Patients Undergoing Peritoneal Perfusion
Condition: Peritoneal Neoplasms
Intervention: Behavioral: Questionnaire
3 Recruiting Goal Directed Therapy (GDT) in Cytoreductive Surgery (CRS) and Hyperthermic Intra Peritoneal Chemotherapy (Hipec)
Conditions: Primary Peritoneal Neoplasm;   Secondary Peritoneal Neoplasm
Interventions: Drug: Goal Directed Intravenous Restrictive Fluid Therapy;   Drug: Conventional Intravenous Fluid therapy
4 Recruiting Effect of Pneumoperitoneum on Cognitive Function and Regional Cerebral Oxygen Saturation
Condition: Pneumoperitoneum
Intervention:
5 Recruiting Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Fallopian Tubes Cancer;   Peritoneal Cancer
Interventions: Procedure: Secondary Cytoreductive Surgery;   Drug: Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC);   Drug: platinum-based systemic chemotherapy postoperatively
6 Recruiting A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Condition: Recurrent Ovarian Carcinoma, Fallopian Tube or Primary Peritoneal Cancer,
Interventions: Biological: Vaccine--‐primed, CD3/CD28--‐costimulated autologous peripheral blood T--‐cells;   Biological: SB--‐485232 (Human recombinant Interleukin--‐18)
7 Unknown  Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP)
Conditions: Spontaneous Bacterial Peritonitis;   Cirrhosis
Interventions: Drug: Standard Care;   Drug: Experimental
8 Recruiting Transcutaneous Electrical Acupoint Stimulation(TEAS) for Hepatic and Renal Dysfunction After Pneumoperitoneum
Conditions: Hepatic Dysfunction Transient;   Renal Function Disorder
Interventions: Other: TEAS pretreatment;   Other: TEAS treatment
9 Recruiting Functional Genomic Influences on Disease Progression and Outcome in Sepsis
Conditions: Pneumonia;   Peritonitis
Intervention:
10 Recruiting Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis
Conditions: Spontaneous Bacterial Peritonitis;   Ascites;   Liver Cirrhosis
Interventions: Drug: Rifaximin;   Drug: Norfloxacin
11 Recruiting Cefotaxime Resistance in Treatment of Spontaneous Bacterial Peritonitis
Condition: Spontaneous Bacterial Peritonitis
Intervention: Drug: Cefotaxime
12 Recruiting Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Conditions: Anxiety Disorder;   Fallopian Tube Cancer;   Fatigue;   Nausea and Vomiting;   Neurotoxicity;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review;   Other: questionnaire administration;   Other: study of socioeconomic and demographic variables;   Procedure: assessment of therapy complications;   Procedure: cognitive assessment;   Procedure: fatigue assessment and management;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
13 Recruiting Obese Patient During RARP: the Role of a Preemptive Ventilator Strategy to Contrast Pneumoperitoneum and Trendelenburg Position
Condition: Obese Patients With Prostate Cancer Disease
Interventions: Other: treatment;   Other: control
14 Recruiting Effect of Deep Neuromuscular Block (NMB), Inhalation or TIVA on Pneumoperitoneum.
Condition: Muscle Relaxation
Interventions: Drug: rocuronium;   Drug: Sevoflurane;   Drug: remifentanyl
15 Recruiting BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer
Condition: Ovarian Cancer, Peritoneal Neoplasms
Intervention:
16 Recruiting The Influence of Pneumoperitoneum on Minimal Invasive Cardiac Output Measurements
Condition: Pneumoperitoneum
Intervention: Procedure: Pneumoperitoneum and SVV/PPV
17 Recruiting Comparison of Low Versus Normal Pressure Pneumoperitoneum - With Profound Low Versus Normal Pressure Pneumoperitoneum -With Profound Muscle Relaxation- During Laparoscopic Donor Nephrectomy
Condition: Renal Disease
Interventions: Procedure: Low pressure pneumoperitoneum;   Procedure: Normal pressure pneumoperitoneum (12 mmHg);   Procedure: Deep neuromuscular block
18 Recruiting TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Solid Neoplasm;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Recurrent Adult Brain Neoplasm;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: TORC1/2 Inhibitor INK128;   Biological: Bevacizumab;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
19 Recruiting Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Stage II Ovarian Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Ovarian Carcinoma
Interventions: Behavioral: Behavioral Dietary Intervention;   Behavioral: Exercise Intervention;   Other: Counseling;   Other: Educational Intervention;   Behavioral: Compliance Monitoring;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
20 Recruiting HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis ‐ Data Registry
Conditions: Peritoneal Neoplasms;   Neoplasm Metastasis;   Adenocarcinoma;   Sarcoma
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years